home · filing · 0001213900-26-060028
8-K
filed May 21, 2026, 4:01 PM ET
ticker CHEC
CIK 0002047177
leadership
confidence high
sentiment neutral
materiality 0.15
Chenghe Acquisition III announces director resignation and appointment
Chenghe Acquisition III Co.
Ningrong Liu resigned from the Board effective May 18, 2026; no disagreement cited.
Zhong Li appointed as independent director effective May 18, 2026, filling the vacancy.
Li designated as Class II director and will serve on Audit, Compensation, and Nominating committees.
Li brings 20+ years of experience from IOSCO, CSRC, BlackRock, and Noah Holdings.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2026-05-18
Filed May 21, 2026, 4:01 PM ET
On May 17, 2026, the Board appointed Zhong Li to serve as an independent director of the Company, effective as of May 18, 2026.
Effective 2026-05-18
Successor Zhong Li
Filed May 21, 2026, 4:01 PM ET
Effective May 18, 2026, Ningrong Liu resigned from the Board of Directors (the “Board”) of Chenghe Acquisition III Co. (the “Company”).
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Zhong Li was appointed as Director at Chenghe Acquisition III Co..
Action appointed
Role Director
Exact text from the filing
On May 17, 2026, the Board appointed Zhong Li to serve as an independent director of the Company, effective as of May 18, 2026.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Ningrong Liu resigned as Director at Chenghe Acquisition III Co..
Action resigned
Role Director
Exact text from the filing
Effective May 18, 2026, Ningrong Liu resigned from the Board of Directors (the “Board”) of Chenghe Acquisition III Co. (the “Company”).
View on SEC.gov
Source: SEC EDGAR
accession 0001213900-26-060028
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.